Know their Lp(a)
Lipoprotein(a), also known as Lp(a), is a critical, independent risk factor for ASCVD, mainly determined by genetics.
Did you know that 1 in 5 people have elevated Lp(a)?
Lp(a) levels ≥125 nmol/L (50 mg/dL) are considered high.
See why testing matters
Testing for Lp(a) levels is essential to have a more complete picture of your patient's cardiovascular risk.
See how proactive testing helps identify high-risk patients and guides earlier, more aggressive risk management.
Learn about testing for Lp(a)
High Lp(a) is associated with up to 4x higher risk for an acute myocardial infarction.
Discover how Lp(a) contributes to cardiovascular risk and why clinical guidelines recommend measuring Lp(a).
Understand the risks of high Lp(a)
ACC/AHA Guideline on the Management of Dyslipidemia now recommends Lp(a) testing as a part of cardiovascular risk assessment for all adults at least once in a lifetime.
In a real-world study of patients with elevated Lp(a), those with other CV risk factors well controlled had a 67% lower relative risk of a CV event.
Consider adding Lp(a) to your patient's next blood draw or lipid panel.
For patients with elevated Lp(a), you can work together to put proactive measures in place to get ahead of cardiovascular disease. Proactive Lp(a) testing enables:
- Lifestyle adjustments
- More intensive risk-factor management
- Earlier initiation of preventive therapies
Help your patients understand their diagnostic options and feel confident about what the testing process involves.
Test for elevated Lp(a) to find out if your patients are at increased risk of a heart attack.
Abbreviations
ASCVD, Atherosclerotic Cardiovascular Disease.
References
- Tsimikas S, Marcovina SM. Ancestry, lipoprotein(a), and cardiovascular risk thresholds. J Am Coll Cardiol. 2022;80(9):934-946.
- Koschinsky ML, Bajaj A, Boffa MB, et al. A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice. J Clin Lipidol. 2024;18:e308-e319.
- Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026;153(17):e1154-e1276.
- Kamstrup PR, Benn M, Tybjaerg-Hansen A, Nordestgaard BG. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation. 2008;117(2):176-184.
- Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43:3925-3946.
- Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31:2844-2853.
- Pearson GJ, Thanassoulis G, Anderson TJ, et al. 2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults. Can J Cardiol. 2021;37:1129-1150.
- Perrot N, Verbeek R, Sandhu M, et al. Ideal cardiovascular health influences cardiovascular disease risk associated with high lipoprotein(a) levels and genotype: The EPIC-Norfolk prospective population study. Atherosclerosis. 2017;256:47-52.
MMAT-06585
Please rate your satisfaction with the content on the following statements:
Very Dissatisfied
Dissatisfied
Neutral
Satisfied
Very Satisfied